<DOC>
	<DOCNO>NCT02136888</DOCNO>
	<brief_summary>The aim study demonstrate therapeutic supratherapeutic plasma exposure ponesimod effect cardiac repolarization exceed threshold regulatory concern measure QTc ( interval begin Q wave end T wave correct heart rate ) interval duration administration multiple oral dos 40 mg 100 mg healthy male female subject .</brief_summary>
	<brief_title>Study Electrocardiographic Effects Ponesimod Healthy Male Female Subjects</brief_title>
	<detailed_description>This Phase 1 , single-center , double-blind , randomize , placebo positive-controlled , double-dummy , parallel group , multiple-dose , up-titration study electrocardiographic effect ponesimod healthy male female subject nest cross-over comparison moxifloxacin placebo . Subjects randomly assign Group A ( ponesimod treatment group ) Group B ( placebo treatment group ) 1:1 ratio . Subjects Group B randomize 1:1 ratio one follow sequence : 400 mg moxifloxacin follow moxifloxacin-matching placebo moxifloxacin match placebo follow 400 mg moxifloxacin .</detailed_description>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Signed informed consent prior studymandated procedure . Body mass index 18.0 30.0 kg/m^2 ( inclusive ) screening . Healthy basis medical history assessment perform screen . Women childbearing potential must negative serum pregnancy test screen negative urine pregnancy test prior first drug administration . Systolic blood pressure 90 150 mmHg diastolic blood pressure 50 90 mmHg . 12lead electrocardiogram ( ECG ) 24hour Holter ECG , without clinically relevant abnormality screen . Hematology clinical chemistry test result deviate normal range clinically relevant extent screening . Negative result urine drug screen screen . Ability communicate well investigator understand comply requirement study . Pregnant lactate woman . Known hypersensitivity moxifloxacin excipients drug formulation . Veins unsuitable intravenous puncture either arm . Treatment another investigational drug within 3 month prior screen . Excessive caffeine consumption , define ≥ 800 mg per day screening . History clinical evidence disease and/or existence surgical medical condition might interfere absorption , distribution , metabolism excretion study drug . Smoking within 3 month prior screen . Any immunosuppressive treatment within 6 week study drug administration . Previous treatment prescribe overthecounter medication within 2 week prior screen five halflives drug , whichever longer . Donation blood , plasma platelet within 3 month prior screen donation make two occasion within 12 month precede first dose administration . Lymphopenia ( &lt; 1,000 cells/μL^9 ) . Viral , systemic , fungal , bacterial protozoal infection within 4 week first study drug administration . History clinical evidence suggestive active latent tuberculosis screening . Positive hepatitis B surface antigen hepatitis C antibody test screen . Positive result human immunodeficiency virus serology screen . FEV1 FVC &lt; 80 % predict value , FEV1/FVC ratio &lt; 0.7 screening . History asthma chronic obstructive pulmonary disease . History atrioventricular block ECG . Any cardiac condition illness ( include ECG abnormality base standard 12lead ECG 24hour Holter ECG screen ) potential increase cardiac risk subject may affect QTc interval analysis . QTc interval &gt; 450 millisecond &gt; 470 millisecond male female subject , respectively ( use ECG machine heart rate correction method ) screening . Heart rate &lt; 50 beat per minute ( bpm ) screen Day 1 predose 12lead ECG . Subjects personal family history long QT syndrome hypokalemia . History fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction . History presence macular edema . History clinical evidence alcoholism drug abuse within 3year period prior screen . Legal incapacity limit legal capacity screen . Any circumstance condition , , opinion investigator , may affect subject 's full participation study compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Ponesimod</keyword>
	<keyword>Safety</keyword>
</DOC>